Is Seladelpar currently available in the country?

Seladelpar has not yet been officially launched in China, which means that domestic patients with primary biliary cholangitis (PBC) cannot obtain the drug directly through local hospitals or pharmacies for the time being. The drug has entered the clinical application stage overseas and has shown good efficacy and safety. Therefore, its introduction and approval in China have also attracted attention. Drug marketing involves strict drug registration and clinical approval processes, including evaluation of pharmacodynamics, safety, pharmacokinetics and clinical efficacy to ensure that new drugs can serve patients safely and effectively after they are launched.

Although it has not yet been launched in the country, some patients may obtain the opportunity to use the drug by participating in international clinical trials or through special import channels. However, this approach must strictly follow the guidance of doctors and relevant laws and regulations. In China, clinicians will conduct traditional treatment and management of patients with chronic cholestatic diseases based on the latest international research progress, and pay attention to the possible future marketing information of Siladepa. The introduction of Siladepa is seen as a potential treatment breakthrough for patients with long-term cholestasis or primary biliary cholangitis, potentially providing a more convenient and safe oral treatment option.

It is worth noting that while waiting for the drug to be launched, patients should maintain regular follow-up and blood index monitoring, continue to use existing standard treatments, such as ulinastatin or ursodeoxycholic acid, and pay attention to new clinical advances and international drug research results. The time for domestic launch depends on the drug registration review and approval process and policy approval. It is expected that after completing the necessary clinical verification and regulatory evaluation, Siladepa will provide new treatment options for domestic patients and bring new hope for the management of cholestatic liver disease.

Reference materials:https://go.drugbank.com/drugs/DB12390